FDA Approves First New Molecular Entity Under National Priority Voucher Program

WHY IT MATTERS

This approval demonstrates the National Priority Voucher program is working to bring new treatment options to patients with rare diseases more quickly than the standard FDA review process.

The FDA approved a new drug called Foundayo (orforglipron) on a special fast-track program called the National Priority Voucher program. This is the fifth drug approved through this program, which helps speed up approval for medicines that address important health needs. The program is designed to get helpful new treatments to patients faster.

The U.S. Food and Drug Administration today approved Foundayo (orforglipron) marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program.

ASK YOUR DOCTOR

If you have the condition Foundayo treats, ask your doctor at your next appointment whether this newly approved medication might be appropriate for you.